Categories: News

Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

MONMOUTH JUNCTION, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com.

For more information about the event, please visit the conference website here.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:

Media Inquiries:

Harriet Ullman
Assistant Vice President
LaVoieHealthScience
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com

Staff

Recent Posts

Aetion Launches Barcelona Technology Hub and Appoints Ken Watson as Chief Technology Officer

BARCELONA, Spain, June 24, 2024 /PRNewswire/ -- Aetion®, the global leader in real-world evidence (RWE)…

2 hours ago

Wearable Patch Market size is set to grow by USD 7.11 billion from 2024-2028, Growing prevalence of chronic diseases to boost the market growth, Technavio

NEW YORK, June 24, 2024 /PRNewswire/ -- The global wearable patch market  size is estimated to grow…

2 hours ago

MyndTec Inc. Completes Sixth Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - June 24, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the…

6 hours ago

Independent Pharmacy Cooperative (IPC) and McKesson Forge New Supply Agreement

SUN PRAIRIE, Wis., June 24, 2024 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC), a leading group…

8 hours ago

Danaher Schedules Second Quarter 2024 Earnings Conference Call

WASHINGTON, June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its…

8 hours ago